Ulipristal acetate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ulipristal acetate and what is the scope of patent protection?
Ulipristal acetate
is the generic ingredient in two branded drugs marketed by Lab Hra Pharma and Teva Pharms Usa, and is included in two NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Ulipristal acetate has sixty-five patent family members in twenty-eight countries.
There are six drug master file entries for ulipristal acetate. Four suppliers are listed for this compound.
Summary for ulipristal acetate
International Patents: | 65 |
US Patents: | 8 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 2 |
Drug Master File Entries: | 6 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 76 |
Clinical Trials: | 56 |
Patent Applications: | 2,385 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ulipristal acetate |
What excipients (inactive ingredients) are in ulipristal acetate? | ulipristal acetate excipients list |
DailyMed Link: | ulipristal acetate at DailyMed |
Recent Clinical Trials for ulipristal acetate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Colorado, Denver | Phase 2 |
University of North Carolina, Chapel Hill | Phase 2 |
University of Utah | Early Phase 1 |
Pharmacology for ulipristal acetate
Drug Class | Progesterone Agonist/Antagonist |
Mechanism of Action | Selective Progesterone Receptor Modulators |
Anatomical Therapeutic Chemical (ATC) Classes for ulipristal acetate
Paragraph IV (Patent) Challenges for ULIPRISTAL ACETATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
ELLA | Tablets | ulipristal acetate | 30 mg | 022474 | 1 | 2014-08-13 |
US Patents and Regulatory Information for ulipristal acetate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ulipristal acetate
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Laboratoire HRA Pharma | ellaOne | ulipristal acetate | EMEA/H/C/001027 Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure. |
Authorised | no | no | no | 2009-05-15 | |
Gedeon Richter Plc. | Ulipristal Acetate Gedeon Richter | ulipristal acetate | EMEA/H/C/005017 Ulipristal acetate is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery. |
Withdrawn | no | no | no | 2018-08-27 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ulipristal acetate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 1232134 | 烏利司他醋酸片 (ULIPRISTAL ACETATE TABLETS) | ⤷ Sign Up |
Croatia | P20161437 | ⤷ Sign Up | |
Japan | 2012523446 | ⤷ Sign Up | |
Poland | 2419108 | ⤷ Sign Up | |
World Intellectual Property Organization (WIPO) | 2011069871 | ⤷ Sign Up | |
Cyprus | 1118099 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.